Yes, in many ways the U.S. is funding China’s defense sector through venture capital, portfolio investments, and computer hardware sales to companies on the Entity List.
The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
U.S. Senator Bill Cassidy (R-LA) has released a discussion draft of a sweeping, ambitious bill titled the “Americas Act”. The bill states its aim to “establish a regional trade, investment, and people-to-people partnership of countries in the Western Hemisphere”. But unlike every other U.S. trade agreement in the last century, the Americas Act actually undertakes…
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
By Charles Benoit, CPA Trade Counsel In December, the U.S.-China Commission, a group created by Congress to advise on managing the bilateral relationship, formally recommended that China lose its Most-Favored Nation (MFN) tariff status. Referencing the decision to grant China permanent MFN status in 2001, Speaker McCarthy said in remarks on the House floor yesterday…
Ambassador Bob Lighthizer, the former U.S. Trade Representative in the Trump administration, joined Laura Ingraham on Fox News Channel to discuss trade, the TPP, and how the Republican Party must embrace a pro-worker trade agenda. Watch the full interview below. LAURA INGRAHAM: Now looking forward to 2024, we see the globalists scrambling to…
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
As 2022 winds down, one thing remains clear, globalization is losing support among policy makers, and even among influencers like Paul Krugman.
The State Department awarded subsidiaries of The Gap in India and Intel in Costa Rica for actions taken by those companies there. Here’s why the parent companies never would have qualified.